Friday, 27 May 2022

Australia's most trusted
source of pharma news

Friday, 27 May 2022

Final PBAC results out today

Posted 17 December 2021 AM

With outcomes of the PBAC's November meeting due later today, Merck's lung cancer therapy Tepmetko is the only drug yet to be TGA approved among the 31 new listings requests, suggesting the company could miss a recommendation this time round.

Merck only received an orphan drug designation for the therapy in July for the treatment of non-small cell lung cancer (NSCLC) in patients with genetic MET alterations, although it also received a provisional determination on the same day, meaning it could be approved in quicker timeframe on the basis of preliminary clinical data.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (9)

Sales & Customer Relations (38)

Access & Reimbursement (4)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (2)

Other (28)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.